Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations Routine +

Therma Bright Announces Follow-On Order from Horizon Health as Venowave(TM) Gains Traction in U.S. Vascular Markets

Therma Bright Secures Repeat Orders, But Scale Remains Questionable Amidst Capital Needs

By The Northwire Desk — AI Analysis May 05, 2026 · 06:31 THRM · 0.065 Therma Bright Inc.
Executive Summary
  • Most Recent News (May 5, 2026): Therma Bright announced a second commercial order of 100 Venowave units from Horizon Health. This follows an initial shipment of 100 units delivered in late March 2026.
  • Product Validation: The device is a battery-operated peristaltic pump for venous insufficiency, reimbursable via Medicare (HCPCS E0683).
  • Distribution Strategy: Horizon Health moves over 35,000 compression products annually; the order leverages their distribution channels.
  • Historical Context:
    • Jan 20, 2026: Follow-on order of 200 units from Gen-X Med (Texas distributor).
    • Mar 31, 2026: Initial commercial order of 100 units from Horizon Health.
    • Feb 10, 2026: Inretio (portfolio company) completed First-in-Human cohort for PREVA Stroke Platform; capital raise needed.
    • Dec 18, 2025: InStatin (portfolio company) pivoted to COPD indication; targeting $35M financing in 2026.
Material Impact
  • Incremental Revenue: The May order confirms the March deal was not a one-off, validating product-market fit for Venowave. However, 100 units represents low absolute revenue compared to typical public company thresholds unless margins are exceptionally high.
  • Capital Needs Risk: While commercial traction is positive, subsidiary companies (Inretio, InStatin) require significant capital ($35M target for InStatin alone). This creates dilution risk or parent-level funding pressure.
  • Transcript Discrepancy: The provided transcript details "Gentherm" with $394 million Q1 revenue and a Modine merger. This contradicts Therma Bright's news scale (hundreds of units vs billions in revenue). This suggests the transcript is irrelevant to Therma Bright or indicates a complex corporate structure not fully disclosed, posing a data integrity risk for valuation models.
  • Market Expectation: The market has already priced in the initial Horizon Health deal (March) and Gen-X Med deal (January). The May news is a confirmation of existing expectations rather than new information.
THRM · Price
Company Overview
  • Company: Therma Bright Inc. (Ticker implied THRM based on URL).
  • Flagship Project: Venowave(TM), a compact, battery-operated peristaltic pump for chronic venous insufficiency and DVT prevention.
  • Portfolio Companies: Inretio (Stroke Neuro-Thrombectomy System PREVA) and InStatin (Inhaled Statin INS-102).
  • Development Stage: Venowave is in commercial sales phase; Inretio and InStatin are in clinical/pre-clinical stages requiring funding.
Read the original news release →

More from Therma Bright Inc.

Jun 23, 2026 · 06:31

Therma Bright Announces Expanded U.S. Orders for Venowave and Mobilizes Supply Chain for Upcoming Sales Volume

Financings Mar 31, 2026 · 15:32

Therma Bright wins order for 100 Venowave units

M&A / Property Mar 31, 2026 · 06:31

[Value]

Other Feb 10, 2026 · 17:09

Therma portfolio co. completes FIH stroke cohort

Regulatory Feb 10, 2026 · 07:01

Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial

Regulatory Jan 20, 2026 · 15:40

Therma Bright receives order for 200 Venowave VW5 units

Other